Sernova Announces Extension of Terms of Warrants
(firmenpresse) - LONDON, ONTARIO -- (Marketwire) -- 10/17/11 -- Sernova Corp. ("Sernova" or the "Company") (TSX VENTURE: SVA) announces that it proposes to extend the term of common share purchase warrants that were issued pursuant to a non-brokered private placement of units of the Company (the "Private Placement") on October 30, 2009.
A total of 3,659,000 units (the "Units") were issued in the 2009 Private Placement, each Unit consisted of one common share of the Company (a "Common Share") and one common share purchase warrant of the Company (a "Warrant"), with each Warrant entitling the holder thereof to acquire one additional Common Share at a price of $0.20 per Common Share. The Warrants are scheduled to expire on October 30, 2011. Subject to TSX Venture Exchange approval, the expiration of the 3,659,000 Warrants will be extended to 4:00 p.m. (Pacific Time) on April 30, 2012.
No Warrants have been exercised to date.
About Sernova
Sernova Corp. is a Canadian-based, health-sciences company focused on commercializing medical technologies. Sernova is currently developing a platform technology for a number of serious disease indications, starting with a novel treatment for insulin-dependent diabetes, using the novel Cell Pouch System™ and its patented Sertolin™ cell technology.
Forward Looking Information This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although Sernova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of Sernova's management on the date such statements were made. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Sernova Corp
Philip Toleikis, Ph.D.
President and CEO
(604) 961-2939
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 17.10.2011 - 10:00 Uhr
Sprache: Deutsch
News-ID 76520
Anzahl Zeichen: 0
contact information:
Town:
LONDON, ONTARIO
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 257 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sernova Announces Extension of Terms of Warrants"
steht unter der journalistisch-redaktionellen Verantwortung von
Sernova Corp (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
